PEDRA Technology, a Singapore-based developer of innovative deep-tissue perfusion monitors, raised $4.7M in Series A financing.
Backers included SEEDS Capital, the investment arm of Enterprise Singapore, M&L Healthcare Investments and two strategic manufacturers of peripheral vascular devices.
The company intends to use the funds for the development of a first-generation system to assess perfusion non-invasively, and drive a clinical program to establish perfusion monitoring as a new standard of care in the treatment of peripheral arterial disease (PAD) and critical limb ischemia (CLI). The technology will also enable to improve detection of compromised tissue perfusion in diabetic feet, which will allow for better triage towards appropriate treatment pathways.
Led by Kareen Looi, CEO, PEDRA Technology is a medical device company that focuses on the use of tissue perfusion monitoring in the field of peripheral artery disease (PAD) and critical limb ischemia (CLI). Its perfusion monitoring system is in advanced development and is not currently approved for sale in the U.S.